Global reports of takotsubo (stress) cardiomyopathy following COVID-19 vaccination: First systematic review and meta-analysis

Sirwan Khalid Ahmed\textsuperscript{1,2}, Mona Gamal Mohamed\textsuperscript{3}, Rawand Abdulrahman Essa\textsuperscript{1,2}, Eman Abdelaziz Ahmed Rashad\textsuperscript{3}, Shukrya Abdulrahman Mohamed\textsuperscript{1}, Awat Alla Khdir\textsuperscript{1}

\textsuperscript{1} Department of Emergency, Rania Pediatric & Maternity Teaching Hospital, Rania, Sulaimani, Kurdistan-region, Iraq

\textsuperscript{2} Department of Biotechnology, Institute of Science and Modern Technology, Rojava University, Qamishlo, Syria

\textsuperscript{3} Department of Adult Nursing, RAK Medical and Health Sciences University, Ras Al Khaimah, UAE

**Corresponding Author:**

Sirwan Khalid Ahmed

Department of Emergency, Rania Teaching Hospital, Rania 46012, Kurdistan region-Iraq, and Department of Biotechnology, Institute of Science and Modern Technology, Rojava University, Qamishlo, Syria

TEL: +9647501553224

Email: sirwan.ahmed1989@gmail.com

Abstract

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Background and aims

Concerns have been raised recently about takotsubo cardiomyopathy after receiving COVID-19 vaccines, particularly the messenger RNA (mRNA) vaccines. The goal of this study was to compile case reports in order to provide a comprehensive overview of takotsubo cardiomyopathy associated with COVID-19 vaccines.

Methods

From inception until March 10, 2022, a systematic literature search was conducted in PubMed and Google Scholar. The study included individuals who developed cardiac takotsubo cardiomyopathy as a result of receiving COVID-19 vaccinations, regardless of the type of vaccine or dose.

Results

Eight studies, including 8 cases, participated in the current systematic review. The median age was 61.6 years; 87.5% were female, while 12.5% were male. 75% of the patients received the mRNA COVID-19 vaccines, while 25% received other types. In addition, takotsubo cardiomyopathy occurred in 62.5% of patients after receiving the first dose and another 25% after the second dose of COVID-19 vaccines. Moreover, the mean number of days to the onset of symptoms was 2.62 days. All cases had an elevated troponin test and abnormal ECG findings. The left ventricular ejection fraction (LVEF) was above 50% among all cases. In terms of the average length of stay in the hospital, 62.5% stayed for 10.2 days, and all cases recovered from their symptoms.

Conclusion

Takotsubo (stress) cardiomyopathy complications that are associated with COVID-19 vaccination are rare, they can be life-threatening. Chest pain should be considered an alarming symptom, especially in those who had received a second dose of the vaccine in the last 3 days. For diagnosis,
CK-MB and troponin are better biomarkers to confirm myocarditis than CRP, ESR, and NT-proBNP. All of cases completely recovered.

**Keywords**

Takotsubo cardiomyopathy, stress cardiomyopathy, COVID-19 Vaccine, mRNA vaccine, BNT162b2, mRNA-1273, ChadOX1 nCOV-19.

**Introduction**

The coronavirus (COVID)-19 pandemic, which was caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has had a negative impact on millions of people all over the world. SARS-CoV-2 vaccines are still the best hope for combating the global pandemic. The FDA granted emergency approval to Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccines in December 2020.

Takotsubo cardiomyopathy (TCM) is a type of heart disease that is frequently triggered by strong physical and/or emotional stress. Although the pathophysiology of this condition is not fully understood, studies have suggested that it may be caused by activation of central autonomic neurons expressing oestrogen receptors, coronary vasospasm, increased sensitivity to a surge in circulating catecholamines and metabolic dysfunction [1]. Catecholamine levels have been found to be higher in TTC than in STEMI [2,3]. TTC cases have risen from 1.5% to 7.8% as a result of the COVID-19 pandemic [4]. TTC has already been linked to a 'cytokine storm' of interleukin 6 (IL-6) and tumor necrosis factor alpha (TNFa), which causes hyperinflammation in COVID-19 patients [5,6]. Individuals who presented without COVID-19 infection or other notable risk factors may have been infected with TTC due to the psychological stress of living in a pandemic [1]. TTC is more likely to occur in people who have a history of mental illness before the outbreak of the pandemic [5,7–9]. Moderna mRNA1273 and Pfizer BioNTech BNT1626b2 (COVID19 mRNA vaccines) induce innate immunity, cytotoxic and helper T cell responses, and in particular B cell responses [10].
Pain, erythema, swelling, fever, headache, and myalgia were the most common systemic or local reactions reported [11]. However, acute myocardial infarction, pulmonary embolism, stroke, and venous thromboembolism are all possible complications of mRNA based COVID19 vaccines [12–14]. There have been reports of takotsubo cardiomyopathy following the COVID-19 vaccination, particularly following the messenger RNA (mRNA) vaccines [1,15–21].

We are aware of no systematic review that has been conducted specifically for COVID-19 vaccines induced stress cardiomyopathy. Given the rarity of adverse takotsubo cardiomyopathy associated with COVID19 vaccination, the majority of the peer reviewed and published papers are case reports. The goal of this study was to compile case reports in order to provide a comprehensive overview of takotsubo cardiomyopathy associated with COVID-19 vaccines.

**Methods**

**Review objectives**

In this study, the primary goal is to clarify the possibility of takotsubo cardiomyopathy associated with COVID-19 vaccination and to elaborate on the demographic and clinical characteristics of COVID-19 vaccinated individuals who develop takotsubo cardiomyopathy.

**Protocol and Registration**

The review follows the PRISMA 2020 guidelines for reporting systematic reviews and meta-analyses [22]. The review protocol was recorded in the International Prospective Register of Systematic Reviews (PROSPERO) under the registration number CRD42022316515. Additionally, the AMSTAR-2 checklist was used to assess the quality of this review, which was found to be of high quality [23]. No ethical approval was required for this review article.

**Search strategy**
A comprehensive search of major online databases (PubMed and Google Scholar) was performed on March 10, 2022, in order to discover all articles that had been published. The search strategy consisted of a combination of the following key words: COVID-19 vaccine AND takotsubo cardiomyopathy OR stress cardiomyopathy. In addition, we checked the references of all relevant papers to ensure the search was complete.

**Eligibility criteria**

1. All case series, and case reports after the COVID-19 vaccine developed takotsubo cardiomyopathy in humans, regardless of the type of vaccine and dose, were included.

2. In this review, narrative and systematic reviews, as well as papers with insufficient data, were excluded. Furthermore, articles written in languages other than English were excluded.

**Data extraction and selection process**

Every step of the data extraction process from the original source was guided by PRISMA 2020, which was used to guide the process. Three independent authors (SKA, RAE, and MGM) used the Rayyan website to screen abstracts and full-text articles based on inclusion and exclusion criteria [24]. Disagreements between the three independent authors were resolved by discussion. The data extraction process was carried out using predefined forms in Microsoft Office Excel. A total of the following information was extracted from each research study: author names, year of publication, age, gender, type of COVID-19 vaccine, dose, troponin levels, days to symptoms onset, symptoms, length of hospital stay/days, ECG, LVEF < 50% or LVEF > 50%, treatment and their outcomes.

**Critical appraisal**

We used the Joanna Briggs Institute's critical appraisal tool for case reports to evaluate all included studies [25]. Each article was evaluated independently by three authors (SKA, MGM, and RAE).
The paper evaluation disagreements were resolved either through discussion or by the first author (SKA). The results of our systematic review were evaluated using the AMSTAR 2 criteria [23]. The overall quality of our systematic review was rated "moderate" by the AMSTAR 2 tool.

**Data synthesis and analysis**

The data from all the articles included in this systematic review were extracted and pooled. This included (author names, year of publication, age, gender, type of COVID-19 vaccine, dose, troponin levels, days to symptoms onset, symptoms, length of hospital stay/days, ECG, LVEF <50% or LVEF >50%, treatment and their outcomes). We collected this information from the findings of eligible studies. Statistical analysis will be performed using the Statistical Package for the Social Sciences (SPSS) 25.0 software program (SPSS Inc, Chicago, IL, USA). Categorical data will be expressed as proportions (%), and numerical data will be expressed as mean ± standard deviation (SD). We pooled the results of the studies into one table.

**Results**

**Selection of studies**

The major databases (PubMed and Google Scholar) yielded 189 articles relevant to our search criteria on March 10, 2022. The references were then organized using a citation manager tool (Mendeley), and seven articles were automatically eliminated because they were duplicate. Then, a final check was performed on 182 articles to ensure that their titles, abstracts, and full texts were accurate. There were 169 articles that were rejected because they did not meet the requirements to be included. Aside from that, 13 articles were submitted for retrieval, with five of them being rejected because they did not meet our inclusion criteria. Finally, our systematic review included only 8 articles (Fig 1). Case report details are shown in (Table 1).

**Characteristics of the included studies**
Table 2 shows an overview of the eight cases. The mean age and SD were 61.62 ±15.70 years; 87.5% were female, while 12.5% were male. 75% of the patients received the mRNA COVID-19 vaccine either from Pfizer-BioNTech (BNT162b2) or Moderna COVID-19 Vaccine (mRNA-1273), while 25% received other types, including Oxford, AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19).

In addition, takotsubo cardiomyopathy occurred in 62.5% of patients after receiving the first dose and another 25% after the second dose of COVID-19 vaccines.

Moreover, the mean number of days to the onset of symptoms was 2.62 ± 2.19 days. All cases had an elevated troponin test and abnormal ECG findings. The left ventricular ejection fraction (LVEF) was above 50% among all cases. In terms of the average length of stay in the hospital, 62.5% stayed for 10.20 ± 3.96 days, and all cases recovered from their symptoms.

Discussion

Purposes of COVID-19 vaccinations

COVID-19 vaccines protect the general public and restrict viral propagation. Inactivated viral, DNA, mRNA, and protein-based vaccines are the four primary mechanisms examined in this research for COVID-19 vaccines. DNA-based vaccinations use viral vectors to deliver the DNA coding for the SARS-CoV-2 spike protein into cells; mRNA vaccines typically deliver mRNA into cells via a lipid nanoparticle; protein vaccines use the spike proteins or their particles, and certain other vaccinations use inactivated viruses [26].
Vaccines are one of the most effective treatments to combat COVID19, saving millions of lives each year. However, the ideal option is a vaccine that is effective, safe, and does not cause serious side effects. Due to the lack of a viable and approved COVID19 treatment, competition for vaccine development began and the 259 COVID19 vaccine project began on November 11, 2020. The rapid development of vaccines raises the potential for vaccine-related safety concerns. Many countries are developing vaccines to protect the population after the COVID 19 pandemic [27].

Many vaccines were available earlier than planned due to urgent needs. New technologies are also helping to develop much more effective vaccines. However, those potential adverse effects must be considered [28].

The COVID-19 pandemic has seen the largest global vaccination program in history with over 11.3 billion vaccination doses administered from December 2020 to December 2021. With increasing populations being vaccinated daily, we are seeing an increase in reports of associated side effects. The most common side effects reported are pain, swelling, and redness around the injection site. Systemic effects such as fever, fatigue, myalgia, and headache can also occur in around one in four. A higher prevalence of these systemic effects has been noted in women, individuals [29].

Moreover, severe side effects have been reported and are under current monitoring: thrombocytopenic thrombosis, anaphylaxis, Bell’s palsy, and capillary leak syndrome [30].

**Pathophysiology and mechanism of injury**

Although the pathophysiology of takotsubo syndrome after Covid19 vaccination is not well established, the proposed hypotheses are Stunning changes in ischemia-induced myocardium secondary to microvessel or multi vascular vasospasm; Direct myocardial injury due to surge currents. Animal studies modelling the octopus trap showed high serum epinephrine levels and high apical-basal levels. Pleiotropic b2-adrenergic receptor gradient in the context of apical myocardial depression, consistent with typical echocardiographic findings of takotsubo syndrome [31].
Also, the mechanism behind this is a controversy for which the decisive mechanism has not yet been identified. Some authors develop cytokine storms, cause systemic inflammatory response syndrome (SIRS), cause broken heart syndrome, and, despite aggressive treatment, cause heart failure that is difficult to withdraw from the ventilator [32].

Acute emotional or physical stressors induce increased levels and bioavailability of catecholamines and cortisol in the blood that mediate multiple pathways. Pericardial coronary artery spasm, microvascular dysfunction, and direct muscle cell injury, are all Key findings of TTS. References to the essential role of catecholamines in TTS include, for example high plasma levels in affected patients and subsequent induction of TTS-like disease, administration of epinephrine or norepinephrine [33].

While producing catecholamines positive inotropic effects of Gs-coupling proteins, they activate 2 adrenergic receptors. The heart tissue is different if high levels of epinephrine (but no epinephrine) are present once secreted, the 2ad receptor switches from Gs to Gi coupling. This switch to Gi is predominant at the apex of heart tissue and is intended to be limited in the degree of myocardial injury during catecholamine surge induced by cardiotoxic activation of 1 and 2 adrenergic receptors Gs pathway [34].

The release of several inflammatory cytokines such as interleukin6 and tumor necrosis factor in the cytokine storm accompanying during a few days’ post vaccinations is multifactorial and mediated by direct effects of cytokine storm and microvascular dysfunction. It is not clear, however, why a high incidence of TTS has been reported during a specific time post-vaccine. Moreover, TTS cases have been reported also following COVID19 vaccinations. It should be noted that disease-induced stress and catecholamine surge may also aggravate these pathways, and such an overlap in mechanisms seems reasonable. Elevated levels of catecholamines have been in aortic roots and coronary sinuses in patients with COVID 19 vaccine and TTS [35,36].
Within our systematic review, half of case reported were in the United States, most of the participants were female, and their mean age 61.62 years old. Other case report who supported that, case of takotsubo cardiomyopathy (TTC) following administration of the second dose of the DNA ChadOX1 nCOV-19 (AZD122) vaccination reported that this condition predominantly affects women (90%) within age 50 and above [1].

Our participants received different types of COVID-19 vaccination as Pfizer-BioNTech or Moderna mRNA-1273, Oxford, AstraZeneca and ChAdOx1 nCoV-19, and more than half of them had only first dose of COVID-19 vaccine. Many studies found the same results, for example Jani. et al 2021, mention that up to now, few cases of takotsubo cardiomyopathy occurred after SARS-CoV-2 vaccines first or second dose administration have been reported even including different types of vaccines (mRNA-1273, mRNA-BNT162b2-Sars CoV-2, and ChAdOx1 nCoV-19 [16]. Also Berto et al 2021, reported A healthy 30-year-old Asian woman was brought to the emergency room with sudden chest pain and cold sweat. She received the second mRNA COVID-19 vaccine shot (Pfizer, New York City) 2 days prior [15].

Symptoms and diagnostic criteria

Patients with symptoms of acute coronary syndrome such as chest pain or dyspnea including changes in the electrocardiogram and release of troponin, etc. Myocardial enzymes and in the absence of serious obstructive coronary artery disease meet the Takotsubo syndrome Mayo Clinic criteria [37].

All patients underwent coronary angiography to eliminate significant obstruction coronary heart disease. Demographics; Symptoms at the time of presentation; ECG, and transthoracic echocardiographic findings; cardiac enzymes, including creatine, Troponin I, and creatine phosphokinase were recorded during hospitalization. In the selected cases, magnetic resonance imaging (CMRI) was performed [38].
Fatigue, nausea, vomiting, diarrhea, muscle aches, weakness, and headaches have also been reported. Often the result of blood tests showed an increase in lactic acid level, etc. Inflammation markers containing creativity proteins (CRP), Erythrocyte sedimentation rate (ESR) and Procalcitonin. It was important to distinguish between fulminant myocarditis and sepsis-induced systemic inflammatory response syndrome (SIRS) Infusion resuscitation, general protocol, exacerbated fulminant myocarditis with fluid overload. Baseline tests for cardiac enzymes as Troponin and N-terminal pro-B sodium diuretic Peptide on admission [39].

TTS is diagnosed according to the Mayo Clinic criteria. According to these criteria, TTS has left ventricular hypokinesia, akinesia, or dyskinesia, and these local wall dyskinesias, with or without apex involvement, are specific epicardial vasculature boundaries. It is diagnosed when it expands beyond. No evidence by angiography of obstructive coronary artery disease or acute plaque rupture; new ST elevation or T wave inversion or mild cardiac troponin elevation; lack of brown cell tumor or myocarditis. TTS mimics myocardial infarction in clinical, electrocardiographic, echocardiographic, and hematological studies. TTS is triggered by emotional, physical, or unknown triggers. However, according to a recent review, physical triggers predominant in male and female patients. The discussion of TTS in index patients is clinical symptoms (abdominal chest pain), ECG (T wave reversal), echocardiography (apical and apex hypomotility), and elevated troponin, CKMB, and proBNP [16,40].

Another important finding in the current systematic review, the initiation of symptoms post vaccine about three days, all of cases had elevated troponin level, the ejection friction above 50% and Electrocardiogram shown abnormal finding.

These findings matched with Toida et al. 2021, who reported that patient had received the first dose of the Pfizer-BioNTech COVID-19 vaccine. The day after the vaccination, she developed general fatigue and loss of appetite. At admission, systolic/diastolic blood pressure was 82/47 mmHg, and heart rate was 114 bpm with an irregular rhythm. A physical examination revealed a systolic
murmur of Levine 2/6 at the second left sternal border, clear lung sounds, and no leg edema. On admission, electrocardiography (ECG) newly revealed atrial fibrillation with a normal axis, negative T-waves in I, aVL, and V3-6, and a prolonged QTc interval of 495 ms [17].

Management and outcome

The clinical results of patients ultimately, Takotsubo cardiomyopathy is not benign the condition is associated with a 5.6% per patient year death 9.9% per patient risk of serious cardiac adverse events. This index of possible ChAdOx1nCov19 Cardiomyopathy indicates the need for vigilance when the assessment of acute coronary syndrome after ChAdOx1 nCov19 vaccination [2].

Supportive cardiac care-optimal management of myocardial injury post-COVID 19 vaccines has not yet been established. Therefore, for the management of patients with myocardial disorders, including patients with suspected TTS, support measures such as angiotensin receptor inhibitor and angiotensin converting enzyme (ACE) inhibitor. Includes, treatment of arrhythmias, and avoidance of heart toxins, alternatively, angiotensin receptor blockers (ARBs), which are used to reduce ejection fraction and treat heart failure [41].

Medical management for Takotsubo cardiomyopathy is based on the presence or absence of hemodynamic stability and other complications. Patients have complications such as acute heart failure without LV outflow tract obstruction should receive diuretics, angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers, and beta-blockers [42].

However, in contrast to the mortality benefit realized in other types of heart failure, therapy with beta-blockers and ACE inhibitors do not discuss significant survival benefits in patients with Takotsubo cardiomyopathy. In addition, only ACE inhibitors were shown to help prevent the recurrence of takotsubo induced cardiomyopathy [43].

The role of aldosterone antagonists has not been well-established, but they have been hypothesized to be potentially cardioprotective due to anticatecholamine effects [44].
Guidelines on the duration of treatment are lacking, but patients are typically treated for 4 weeks until improvement of LVEF is seen. There are no studies that have evaluated the role of goal-directed medical therapy on atypical variant takotsubo [18].

Patients with takotsubo syndrome generally have a good prognosis. An outcomes study assessing trends of hospitalized patients with takotsubo cardiomyopathy demonstrated an in-hospital mortality rate of 1.3% [95% confidence interval (CI) 1.1–1.6], hospital discharge rate to the home of 73.6% (95% CI 72.7–74.6), and 1-year mortality of 6.9% (95% CI 6.4–7.5) [45]. Consistent with the prior case experiences of post-DCCV takotsubo syndrome, and was discharged home without the need for post-acute care services. Repeat TTE at 2 months showed complete global and regional restoration of LV function [46].

We found more than half of the patients length of hospital stay Mean ± SD were 10.20 ± 3.96 days and all of them recovered without any complications.

These finding in contract with Toida et al. 2021, who shown the case report regarding takotsubo cardiomyopathy after covid-19 vaccine and found the patient length of hospital stay about 5 days’ post-event [17].

Support our finding by Đenić et al. 2022, who reported the patient improved clinically and had no evidence of high-risk features on 12-lead ECG or TTE. The patient was followed up after 3 months. Her follow-up CMR showed resolving myocardial oedema in the apex and septum. Repeat TTE showed normal left ventricular (LV) systolic function and resolution of previously noted wall motion abnormalities [47].

While takotsubo cardiomyopathy after covid-19 vaccine pathogenesis is incompletely understood, catecholamine excess mediated myocardial stunning is favoured, with excess release precipitated by a physical or emotional triggering event. Primarily seen in ageing women, the diagnosis of takotsubo of presentation and triggers, characteristic imaging and exclusion of acute coronary
syndrome and myocarditis. Cytokine storm has been described with an excessive and uncontrolled inflammatory response, and there is a feedback loop between catecholamines and cytokines [48].

**Limitation**

We recognize that our systematic review has some limitations, which include; we only involved case reports and case series, due to the limited numbers of original studies published on the takotsubo cardiomyopathy after taken COVID-19 vaccines so the results should be interpreted with some caution. Moreover, we do not have any data about the previous history of COVID-19, which may affect the results, since COVID-19 can also cause cardiac complications.

**Conclusion**

Takotsubo (stress) cardiomyopathy complications that are associated with COVID-19 vaccination are rare, they can be life-threatening. Chest pain should be considered an alarming symptom, especially in those who had received a second dose of the vaccine in the last 3 days. For diagnosis, CK-MB and troponin are better biomarkers to confirm myocarditis than CRP, ESR, and NT-proBNP. All of cases had completely recovery without any irreversible cardiomyopathy changes.

Current recommendations recommend that in the case of myocardial pericarditis, the second dose of the Covid19 vaccine should be postponed to allow for a second dose of the vaccine after the symptoms have completely disappeared.

**Conflicts of interest**

There is no conflict to be declared.

**Funding**
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author Agreement Statement

We declare that this manuscript is original, has not been published before and is not currently being considered for publication elsewhere. We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We confirm that the order of authors listed in the manuscript has been approved by all of us. We understand that the Corresponding Author is the sole contact for the Editorial process. He is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs.

Data availability Statement

All relevant data are within the manuscript and its supporting information files.

Authors’ contributions: Conception and design SKA acquisition of data SKA, RAE, MGM, EAA analysis and interpretation of data SKA, MGM, EEA, drafting of the manuscript SKA, RAE, MGM, EAA and SAM critical revision of the manuscript for important intellectual content statistical analysis SKA, MGM, RAE, EEA, SAM and AAK administrative SKA, MGM, EAA technical SKA, supervision SKA, RAE and all authors approving final draft.

Provenance and peer review

Not commissioned, externally peer-reviewed

Acknowledgments

Not applicable
References


Fig 1: PRISMA flow diagram
Table 1: Characteristics and outcomes of patients with takotsbo cardiomyopathy related to COVID-19 vaccine.

<table>
<thead>
<tr>
<th>Author/Year of publication</th>
<th>Country</th>
<th>Age/years</th>
<th>Gender</th>
<th>Type of vaccine</th>
<th>Dose of vaccine</th>
<th>Days to symptom onset</th>
<th>Symptoms</th>
<th>Troponin level</th>
<th>LVEF &lt;50% or LVEF &gt;50%</th>
<th>Electrocardiogram (ECG)</th>
<th>Length of hospital stay (days)</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Berto et al 2021 [15]</td>
<td>Switzerland</td>
<td>63</td>
<td>Female</td>
<td>mRNA-1273</td>
<td>1st</td>
<td>1</td>
<td>dyspnoea and fever.</td>
<td>Elevated</td>
<td>LVEF &lt;50%</td>
<td>Abnormal</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Jani et al 2021 [16]</td>
<td>United States</td>
<td>65</td>
<td>Female</td>
<td>mRNA-1273</td>
<td>1st</td>
<td>1</td>
<td>Chest pain, myalgia, nausea, headache</td>
<td>Elevated</td>
<td>LVEF &lt;50%</td>
<td>Abnormal</td>
<td>Abnormal</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Reiko Toida et al 2021 [17]</td>
<td>Japan</td>
<td>80</td>
<td>Female</td>
<td>BNT162b2</td>
<td>1st</td>
<td>1</td>
<td>General fatigue, loss of appetite</td>
<td>Elevated</td>
<td>LVEF &lt;50%</td>
<td>Abnormal</td>
<td>Abnormal</td>
<td>13</td>
<td>Aspirin, atorvastatin, lisinopril, metoprolol succinate</td>
</tr>
<tr>
<td>Caitlin Stewart et al 2021 [1]</td>
<td>United Kingdom</td>
<td>50</td>
<td>Female</td>
<td>mRNA-1273</td>
<td>2nd</td>
<td>7</td>
<td>Chest pain</td>
<td>Elevated</td>
<td>LVEF &lt;50%</td>
<td>Abnormal</td>
<td>Abnormal</td>
<td>5</td>
<td>Oxygen, IV fluid</td>
</tr>
<tr>
<td>Colleen Fearon et al 2021 [18]</td>
<td>United States</td>
<td>73</td>
<td>Female</td>
<td>ChadOX1nCOV-19</td>
<td>NA</td>
<td>1</td>
<td>chest pain, shortness of breath, fatigue, nausea</td>
<td>Elevated</td>
<td>LVEF &lt;50%</td>
<td>Abnormal</td>
<td>Abnormal</td>
<td>8</td>
<td>Dual antiplatelet therapy</td>
</tr>
<tr>
<td>Hiroki Yamaura et al 2022 [19]</td>
<td>Japan</td>
<td>30</td>
<td>Female</td>
<td>mRNA-1273</td>
<td>2nd</td>
<td>1</td>
<td>chest pain and cold sweat</td>
<td>Elevated</td>
<td>LVEF &lt;50%</td>
<td>Abnormal</td>
<td>Abnormal</td>
<td>15</td>
<td>metoprolol succinate, losatan</td>
</tr>
<tr>
<td>Phillip Crane et al 2021 [20]</td>
<td>Australia</td>
<td>72</td>
<td>Male</td>
<td>BNT162b2</td>
<td>1st</td>
<td>2</td>
<td>Chest pain, fatigue and myalgias, fever</td>
<td>Elevated</td>
<td>LVEF &lt;50%</td>
<td>Abnormal</td>
<td>Abnormal</td>
<td>4</td>
<td>The patient was managed without medical therapies</td>
</tr>
<tr>
<td>Mahesh K. Vidula et al 2021 [21]</td>
<td>United States</td>
<td>60</td>
<td>Female</td>
<td>ChadOX1nCOV-19</td>
<td>2nd</td>
<td>4</td>
<td>Chest pain</td>
<td>Elevated</td>
<td>LVEF &lt;50%</td>
<td>Abnormal</td>
<td>Abnormal</td>
<td>NA</td>
<td>patient received appropriate introduction and titration of therapy</td>
</tr>
</tbody>
</table>

Outcome: Discharged
Table 2: Summary of pooled data from included published research papers have been reported in the literature (n = 8)

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (Mean ± SD)</strong></td>
<td>61.62 ±15.70 years</td>
</tr>
<tr>
<td><strong>Gender (n) %</strong></td>
<td>Male – 1 (12.5%)</td>
</tr>
<tr>
<td></td>
<td>Female – 7 (87.5%)</td>
</tr>
<tr>
<td><strong>Type of COVID-19 vaccine (n) %</strong></td>
<td>Pfizer-BioNTech (BNT162b2) – 3 (37.5%)</td>
</tr>
<tr>
<td></td>
<td>Moderna COVID-19 Vaccine (mRNA-1273) - 3 (37.5%)</td>
</tr>
<tr>
<td></td>
<td>Oxford, AstraZeneca COVID-19 vaccine ChAdOx1 nCoV-19 – 2 (25%)</td>
</tr>
<tr>
<td><strong>Dose (n) %</strong></td>
<td>First dose – 5 (62.5%)</td>
</tr>
<tr>
<td></td>
<td>Second dose – 2 (25%)</td>
</tr>
<tr>
<td></td>
<td>None reported 1 (12.5%)</td>
</tr>
<tr>
<td><strong>Days to symptom onset (Mean ± SD)</strong></td>
<td>2.62 ± 2.19 days</td>
</tr>
<tr>
<td><strong>Troponin level (n) %</strong></td>
<td>Elevated – 8 (100%)</td>
</tr>
<tr>
<td></td>
<td>Not elevated – 0 (0%)</td>
</tr>
<tr>
<td><strong>Left ventricular ejection fraction LVEF (n) %</strong></td>
<td>LVEF &gt;50% - 8 (100%)</td>
</tr>
<tr>
<td></td>
<td>LVEF &lt;50% - 0 (0%)</td>
</tr>
<tr>
<td><strong>Electrocardiogram (ECG) (n) %</strong></td>
<td>Abnormal – 8 (100%)</td>
</tr>
<tr>
<td></td>
<td>Normal – 0 (0%)</td>
</tr>
<tr>
<td><strong>Length of hospital stay (days) (Mean ± SD)</strong></td>
<td>10.20 ± 3.96 days in 5 patients</td>
</tr>
<tr>
<td></td>
<td>Unknown in 3 patients</td>
</tr>
<tr>
<td><strong>Outcome</strong></td>
<td>Recovered – 8 (100%)</td>
</tr>
</tbody>
</table>